Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
SomnoMed Limited (SOMNF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of SomnoMed Limited $0.51, price $0.24, upside +112.5%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? No
- Add to watchlist
SL
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
SomnoMed Limited
SOMNF · USCheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.
✓Fair value $0.5100 · Strongly undervalued (+112.5%)
!Quality 41/100
!Mixed Growth (revenue 5y +14.2 %/yr)
!Loss-making · -2.2% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 22/100
!Evidence only low, so the estimate is less certain
Watch SomnoMed Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.1300 – $2.00 · fair‑value band $0.3600 – $0.8400 · the $0.2400 price screens below the $0.5100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea.
Show more
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Stock analysis
SomnoMed Limited (SOMNF) currently trades at $0.2400, while our model-based Fair Value estimate is $0.5100, implying the stock looks roughly 52.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.5000 per share, and 10 of the 13 models we run sit above the $0.2400 price.
Bear case: the Earnings-Based group reads lowest at $0.1400, and 3 of the 13 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3600 (bear) to $0.8400 (bull), the price of $0.2400 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SomnoMed Limited reported revenue of $111M in FY2025 versus $62.7M in FY2021, a compound +15.5%/yr. Reported net income was −$3.5M in FY2025.
Key figures
Market cap $93.3M · P/S ratio 0.79 · EPS (TTM) $−0.0100 · Dividend yield 4.8% · Net margin −3.1% · Return on equity −5.3% · Return on assets (EBIT) −4.5% · Operating margin 4.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 113%, SOMNF screens cheaper than that median.
Fair Value models
Bear $0.3600
Fair Value $0.5100
Bull $0.8400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.3700
$0.5000
$0.8500
79
Growth DCF
$0.3500
$0.5200
$0.8000
78
EPV
$0.1300
$0.1400
$0.1500
74
All 13 models by family
DCF Models
FCF DCF
$0.3700
$0.5000
$0.8500
79
5Y Revenue Exit
$0.2800
$0.4100
$0.6700
71
5Y EBITDA Exit
$0.4500
$0.7900
$1.40
72
10Y Revenue Exit
$0.3000
$0.4800
$0.6400
67
10Y EBITDA Exit
$0.4100
$0.7700
$1.44
65
Earnings-Based
EPV
$0.1300
$0.1400
$0.1500
74
Multiples
EV/EBIT
$0.2900
$0.3600
$0.4300
66
EV/EBITDA
$0.5200
$0.6700
$0.8200
67
EV/Revenue
$0.2300
$0.2900
$0.3500
54
Asset-Based
NCAV (Graham)
$0.1100
$0.1400
$0.2100
54
Growth DCF
Growth DCF
$0.3500
$0.5200
$0.8000
78
Rev-Margin DCF
$0.2800
$0.4400
$0.6900
71
Economic Profit
ROIC Compounder
$0.1300
$0.1400
$0.1500
72
Notify me when SOMNF reaches fair value
Put SOMNF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
41/100
Of which business quality 46 · Market factors (momentum, volatility) 16
Profitability
41
Margins and returns on capital today
Quality Growth
82
Are margins and returns improving?
Cashflow
41
Earnings quality: real cash, not paper profit
Fin. Strength
63
Balance sheet, leverage, solvency risk
Investment
49
Disciplined investing over empire-building
Low Volatility
38
Calm price path (market factor)
Momentum
12
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
0
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
Start year 2020 (pandemic). Over 10 years: +12.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.6% (2019) → −9.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −8.7% a year for the price and +5.9% for the forecasts.
Forecast 2026 (sales)+9.5%
Forecast 2027 (sales)+9.5%
Projected 2028 (sales)+8.6%
Projected 2029 (sales)+7.6%
Projected 2030 (sales)+6.7%
Watch SOMNF, get fair value alerts →
Compare SomnoMed Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is SomnoMed Limited (SOMNF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.5100 versus a price of $0.2400, about +113% upside (undervalued).
What is the fair value of SOMNF?
Our model-based fair value for SomnoMed Limited is $0.5100 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.2400.
What is the quality score of SOMNF?
SomnoMed Limited has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SomnoMed Limited (SOMNF)?
Our model-based price target is the fair value of $0.5100 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario $0.3600, optimistic scenario $0.8400. It is a calculation from audited fundamentals, not an analyst target.
What is the SomnoMed Limited stock forecast for 2026?
Our models put fair value at $0.5100, about +113% upside versus a price of $0.2400 (undervalued). Cautious scenario $0.3600, optimistic scenario $0.8400. The calculation is refreshed regularly with new filings.
What is the revenue of SomnoMed Limited (SOMNF)?
SomnoMed Limited reported trailing-twelve-month revenue of about $119M (latest available figure, as of Sep 24, 2026).
Does SomnoMed Limited pay a dividend?
SomnoMed Limited currently shows a dividend yield of about 4.77% relative to its recent price (as of Sep 24, 2026).
What growth is priced into SomnoMed Limited (SOMNF)?
For today's price to be fair in a discounted-cash-flow model, SomnoMed Limited would have to grow free cash flow by -6.6 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SOMNF use?
Our models discount SomnoMed Limited at 12.1 %: a base by market capitalisation (micro), damped by beta 0.81, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SomnoMed Limited that is -6.6 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has SomnoMed Limited (SOMNF) delivered so far?
Over the past 5 years revenue at SomnoMed Limited grew +14.2 % a year. The price currently implies -6.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SomnoMed Limited (SOMNF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into SomnoMed Limited (-6.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SomnoMed Limited (SOMNF)?
The free-cash-flow yield on the price is 10.54 %: that much free cash flow SomnoMed Limited produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SomnoMed Limited (SOMNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SomnoMed Limited it is $0.5100 per share (as of Sep 24, 2026), against a price of $0.2400. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is SomnoMed Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SOMNF trades below its calculated fair value: price $0.2400, fair value $0.5100, a gap of about +113% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOMNF?
No. The price is what the market pays today ($0.2400); the fair value is what the company's own numbers justify ($0.5100). For SomnoMed Limited the two are $0.2700 per share apart. That gap is exactly why we show both numbers side by side.
How much is SomnoMed Limited worth?
The market values SomnoMed Limited at about $93.3M (market capitalisation, as of Sep 24, 2026). Per share that is $0.2400; our models calculate a fair value of $0.5100 per share.
What do the bullish and bearish scenarios say about SOMNF?
Our models span a range for SomnoMed Limited: cautious scenario $0.3600, base $0.5100, optimistic $0.8400 per share (as of Sep 24, 2026, price $0.2400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SomnoMed Limited (SOMNF)?
Balance-sheet figures for SomnoMed Limited (as of Sep 24, 2026): return on equity −5.3%, debt of 0.02 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is SOMNF from its 52-week high?
SomnoMed Limited trades at $0.2400, about 53% below its 52-week high of $0.5100 and at the low of $0.2400 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5100 is for.
Which stocks are comparable to SomnoMed Limited?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SomnoMed Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $0.2400, calculated fair value $0.5100 (+113%), Quality Score 41/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SOMNF calculated?
We run SomnoMed Limited through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. SomnoMed Limited currently trades 53 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SomnoMed Limited (SOMNF)?
The closing price on Oct 2, 2026 was $0.2400. Our model-based fair value is $0.5100, about +113% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SomnoMed Limited right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.3600). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3600 to $0.8400) leaves room in how you read the outcome.
Key figures of SomnoMed Limited
How large is the market capitalisation of SomnoMed Limited (SOMNF)?
The market capitalisation of SomnoMed Limited is $93.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SomnoMed Limited (SOMNF)?
The price-to-sales ratio of SomnoMed Limited is 0.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SomnoMed Limited (SOMNF)?
Earnings per share at SomnoMed Limited are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SomnoMed Limited (SOMNF)?
The dividend yield of SomnoMed Limited is 4.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SomnoMed Limited (SOMNF)?
The net margin of SomnoMed Limited is −3.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SomnoMed Limited (SOMNF)?
The return on equity (ROE) of SomnoMed Limited is −5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SomnoMed Limited (SOMNF)?
On an EBIT basis the return on assets of SomnoMed Limited is −4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SomnoMed Limited (SOMNF)?
The operating margin of SomnoMed Limited is 4.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SomnoMed Limited (SOMNF)?
Revenue at SomnoMed Limited is growing +13.0% versus a year earlier (3y avg +15.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SomnoMed Limited (SOMNF)?
Earnings per share at SomnoMed Limited are growing −52.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SomnoMed Limited (SOMNF) hold?
SomnoMed Limited holds more cash than debt, $9.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch SomnoMed Limited in the live analysis
One click puts SomnoMed Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.